PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
8.12%
Some net income increase while VET is negative at -1.27%. John Neff would see a short-term edge over the struggling competitor.
3.17%
D&A growth well above VET's 2.21%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-144.13%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
No Data
No Data available this quarter, please select a different quarter.
-24.04%
Both reduce yoy usage, with VET at -231.24%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.04%
Both reduce yoy usage, with VET at -231.24%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
17.70%
Well above VET's 34.97%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
1.12%
Some CFO growth while VET is negative at -54.66%. John Neff would note a short-term liquidity lead over the competitor.
3.05%
Lower CapEx growth vs. VET's 12.62%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-176.63%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-44.23%
We reduce yoy other investing while VET is 84.95%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-117.85%
We reduce yoy invests while VET stands at 25.04%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
88.59%
Debt repayment growth of 88.59% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-5.86%
Both yoy lines negative, with VET at -86.10%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
-11.86%
We cut yoy buybacks while VET is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.